Gene Editing Patents

Gene editing predates CRISPR by more than a decade, and several alternative platforms have distinct patent landscapes that remain commercially relevant: ZINC FINGER NUCLEASES (ZFNs): ZFNs combine engineered zinc finger protein DNA-binding domains with the FokI nuclease catalytic domain; the zinc finger domain can be engineered to recognize specific DNA sequences; SANGAMO THERAPEUTICS IP: Sangamo holds the dominant ZFN patent portfolio, accumulated through internal research and licenses from the Medical Research Council (MRC) in the UK; Sangamo's patents cover zinc finger protein engineering, their DNA binding properties, and therapeutic applications; Sangamo has licensed ZFN technology broadly and has been a pioneer in ZFN clinical applications (first ZFN-based therapies in clinical trials); ZFN PATENT CONSIDERATIONS: ZFN patents cover the protein engineering methods (OPEN platform; CoDA method); specific ZFN pair designs; the split intein delivery method for in vivo ZFN delivery; key limitation: ZFN engineering is complex and each ZFN must be re-engineered from scratch for each target — this limits scalability; TALENs (TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASES): TALENs use TAL effector DNA-binding domains (from Xanthomonas bacteria) fused to the FokI nuclease; TAL effector domains have a modular code that makes engineering more predictable than ZFNs; UNIVERSITY AND ACADEMIC IP: foundational TALEN patents come from Iowa State University and University of Iowa; significant TALEN IP also at UC Berkeley; CELLECTIS TALEN IP: Cellectis holds extensive TALEN patents particularly for therapeutic applications; Cellectis pioneered the use of TALENs for allogeneic (off-the-shelf) CAR-T cell engineering; ERCTA TALEN platform: used for ex vivo cell editing applications where the large protein size is not an obstacle; MEGANUCLEASES: meganucleases (also called homing endonucleases) are naturally occurring large single-chain proteins with inherent DNA binding and cutting activity; Precision BioSciences holds a key patent portfolio on engineered meganucleases and combined megaTAL platforms (meganuclease + TAL effector); advantages: single protein (smaller AAV payload); high natural specificity; disadvantages: each needs extensive re-engineering for new targets; BASE EDITING (beyond CRISPR section — see /crispr-patents): cytosine base editors (CBE) and adenine base editors (ABE) represent a major evolution beyond simple DSB-creating nucleases; Broad Institute/David Liu patents are dominant; Beam Therapeutics is the primary commercial licensee; these are covered in detail in the CRISPR patents guide.

The delivery system is often the most commercially critical and complex part of the gene therapy patent landscape because it determines how the editing machinery reaches the target cells: AAV (ADENO-ASSOCIATED VIRUS) DELIVERY — THE DOMINANT IN VIVO PLATFORM: AAV is a small, non-pathogenic virus used as a delivery vehicle for gene therapy and in vivo gene editing; the virus is engineered to be replication-defective (incapable of spreading) but still capable of delivering its genetic payload; KEY AAV PATENT HOLDERS: SPARK THERAPEUTICS/ROCHE: key AAV patents, particularly for retinal gene therapy applications; marketed Luxturna (voretigene neparvovec) — first FDA-approved in vivo gene therapy in the US (2017); AVEXIS/NOVARTIS: key patents on AAV9 serotype for CNS delivery; Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy (2019); VOYAGER THERAPEUTICS: AAV capsid engineering patents; novel serotypes with improved tissue tropism; PENN VECTOR PROGRAM/UNIVERSITY OF PENNSYLVANIA: James Wilson lab; multiple AAV patents including AAVrh10 serotype; CAPSID ENGINEERING PATENTS: much of the current innovation in AAV delivery involves engineering the capsid protein to improve tissue targeting, immune evasion, and manufacturing yield; directed evolution approaches (shuffle, ACSF) have generated novel AAV variants; companies like Dyno Therapeutics (ML-guided capsid engineering) have patent positions on AI-optimized AAV capsids; AAV MANUFACTURING PATENTS: triple transfection manufacturing; baculovirus-insect cell systems; suspension manufacturing for scale; ultracentrifugation vs. ion exchange purification; LNP (LIPID NANOPARTICLE) DELIVERY: critical for ex vivo applications (delivering mRNA or RNP complexes to cells outside the body); ALNYLAM PHARMACEUTICALS: fundamental LNP patents including ionizable lipid compositions for siRNA delivery; ARBUTUS BIOPHARMA: key LNP patents covering essential ionizable lipid components; important ongoing patent disputes with Moderna over COVID mRNA vaccine LNP IP; PRECISION NANOSYSTEMS/CYTIVA: microfluidic mixing equipment patents for LNP manufacturing; FREEDOM-TO-OPERATE FOR GENE THERAPY: a complete FTO analysis must cover: (1) the editing tool (ZFN; TALEN; CRISPR; meganuclease); (2) the specific delivery system (AAV serotype; LNP composition; lentiviral vector design); (3) the target disease indication (method of treatment patents); (4) the manufacturing process; (5) any novel cell types or compositions produced (e.g., engineered T cells for CAR-T); the overlapping patent landscape means that gene therapy companies almost always operate under multiple licenses, and licensing negotiations can be as complex as the science itself.

Gene therapy and gene editing patents face multiple patent law challenges beyond the standard prosecution hurdles: PATENT ELIGIBILITY (§ 101) CHALLENGES: NATURAL GENE SEQUENCES: following Myriad Genetics (S.Ct. 2013), a naturally occurring gene sequence — even isolated — is not patentable; however, the therapeutic construct in gene therapy is NOT the natural gene; it is an engineered expression cassette (promoter + coding sequence + poly-A signal + ITRs + regulatory elements + sometimes exon optimizations) placed in a non-natural delivery vehicle; this construct as a whole is NOT a product of nature; SPECIFIC ELIGIBILITY CONSIDERATIONS: VIRAL VECTOR WITH TRANSGENE: a specific recombinant AAV vector containing a particular therapeutic transgene expression cassette = patent-eligible (it is an engineered non-natural composition); the vector itself with its specific components is not found in nature; GUIDE RNA SEQUENCES: synthetic guide RNAs (sgRNAs) designed to target specific human disease genes = patent-eligible (synthetic design); ENGINEERED PROTEINS: engineered nucleases (ZFN; TALEN; meganuclease; modified Cas9) = patent-eligible (not natural proteins); DIAGNOSTIC CLAIMS USING GENE THERAPY: if claiming the correlation between a gene mutation and disease for diagnostic purposes, Mayo analysis applies; WRITTEN DESCRIPTION AND ENABLEMENT: ENABLEMENT FOR GENE THERAPY: the specification must enable a person of ordinary skill to make and use the gene therapy product without undue experimentation; Wands factors: quantity of experimentation required; degree of direction provided; presence of working examples; nature of the invention; REPRESENTATIVE EXAMPLES: a strong gene therapy patent application includes: specific vector sequences (full AAV vector map with all elements); production cell line details; in vitro and in vivo efficacy data; safety and biodistribution data; dose-response data (preclinical); WRITTEN DESCRIPTION FOR GENUS CLAIMS: if claiming a genus of vectors (e.g., any AAV serotype delivering the transgene), the genus must be enabled across its full scope; narrow claiming with representative specific embodiments is generally safer; POST-MYRIAD PROSECUTION STRATEGY: focus claims on the specific engineered construct rather than on the natural disease gene; include detailed sequence information in the specification; claim the combination of engineering elements rather than individual elements; describe the functional advantages that distinguish the construct from natural sequences.

The FDA regulatory pathway for gene therapy products creates important interactions with patent strategy that are unique to this field: GENE THERAPY REGULATORY CLASSIFICATION: the FDA regulates gene therapy products as biologics under the Public Health Service Act (PHSA), specifically under the same § 351(a) BLA pathway used for other biologics; gene therapies are NOT regulated under 21 U.S.C. § 505 (drugs/small molecules) — they do not use the Hatch-Waxman ANDA pathway; gene therapies receive the BPCIA 12-year data exclusivity upon BLA approval (NOT the 5-year NCE exclusivity); ORPHAN DRUG DESIGNATION: many gene therapies target rare diseases (affecting < 200,000 US patients); orphan drug designation is common; the 7-year orphan exclusivity stacks with the 12-year biologics exclusivity; this combination provides extremely strong regulatory protection for gene therapies; total exclusivity: 12 years (biologics) + 7 years (orphan, if conditions met) = effectively 12-year floor, potentially longer with pediatric extension; PATENT STRATEGY INTERACTIONS WITH REGULATORY FILING: PRIOR ART CONSIDERATIONS: each FDA regulatory submission (IND; BLA) is a potential prior art disclosure once made public; careful timing of patent filings relative to IND and BLA submissions is essential; the 1-year grace period under AIA § 102(b) protects inventors but only for their own disclosures; PATENT TERM EXTENSION (PTE) UNDER 35 U.S.C. § 156: gene therapy products approved under § 351 BLA are eligible for patent term extension; up to 5 years of PTE for the regulatory review period; 14-year post-approval cap; only one PTE per product; COMBINATION WITH REGULATORY EXCLUSIVITY: combining PTE + 12-year biologics + 7-year orphan + 6-month pediatric extension creates a very long total exclusivity window for novel gene therapies; FAST TRACK, BREAKTHROUGH THERAPY, AND ACCELERATED APPROVAL: gene therapies frequently receive fast track or breakthrough therapy designation; these shorten FDA review time; shorter review time = less time lost to regulatory delays = potentially less PTE benefit but faster market entry; GENE THERAPY BIOSIMILAR STATUS: no gene therapy has yet faced a biosimilar challenge as of early 2026; the 12-year biologics exclusivity effectively prevents this for the near future; the complexity of gene therapy manufacturing makes biosimilar development even harder than for protein biologics.